Title |
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
|
---|---|
Published in |
Journal for Immunotherapy of Cancer, October 2014
|
DOI | 10.1186/s40425-014-0034-0 |
Pubmed ID | |
Authors |
Stefanie J Mandl, Ryan B Rountree, Tracy B dela Cruz, Susan P Foy, Joseph J Cote, Evan J Gordon, Erica Trent, Alain Delcayre, Alex Franzusoff |
Abstract |
PROSTVAC®, an active immunotherapy currently studied for the treatment of metastatic castration-resistant prostate cancer (mCRPC), consists of a heterologous prime-boost regimen with two different poxvirus-based vectors to provoke productive immune responses against prostate specific antigen (PSA) as the target tumor antigen. A Phase 2 study of PROSTVAC immunotherapy showed significantly improved median overall survival by 8.5 months and is currently being validated in a global Phase 3 study (PROSPECT; NCT01322490). Here, preclinical models were explored to investigate the mechanism of action and immune signatures of anti-tumor efficacy with PROSTVAC immunotherapy with the goal to identify potential immune correlates of clinical benefit. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 2% |
France | 1 | 2% |
Unknown | 49 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 14 | 27% |
Student > Master | 8 | 16% |
Student > Bachelor | 6 | 12% |
Student > Ph. D. Student | 5 | 10% |
Professor | 2 | 4% |
Other | 7 | 14% |
Unknown | 9 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 17 | 33% |
Agricultural and Biological Sciences | 8 | 16% |
Immunology and Microbiology | 8 | 16% |
Biochemistry, Genetics and Molecular Biology | 4 | 8% |
Earth and Planetary Sciences | 1 | 2% |
Other | 3 | 6% |
Unknown | 10 | 20% |